MetaCap

Actuate Therapeutics (ACTU) vs Bolt Biotherapeutics (BOLT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Actuate Therapeutics is the larger company by market cap ($13.6 million vs $12.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACTU-68.89%BOLT+36.39%
+91%+6%-78%
Oct 7, 20261 yearNov 20, 2026
ACTU-63.08%BOLT+19.46%
+67%-1%-69%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACTU versus BOLT key metrics
MetricACTUBOLT
Share price$0.2253$4.91
Market cap$13.60M$12.80M
1-day change+5.38%-2.96%
YTD return-96.32%—
1-year return-96.43%—
EPS (TTM)$-0.76$-14.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$7.70M
Revenue growth (YoY)—+0.07%
Net income (latest FY)$-22.23M$-33.38M
Operating margin—-469.30%
Net margin—-433.74%
52-week high$7.90$7.78
52-week low$0.174$3.10
Distance from 52-week high-97.15%-36.89%
Analyst consensusnonenone
Avg. price target upside+5084.20%+490.63%
Average volume807.24K257.43K
Shares outstanding60.38M2.61M
Employees1223
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Actuate Therapeutics

ACTU stock →

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

About Bolt Biotherapeutics

BOLT stock →

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory.

Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees

ACTU vs BOLT FAQ

Which is bigger, Actuate Therapeutics or Bolt Biotherapeutics?

Actuate Therapeutics (ACTU) is larger, with a market capitalization of $13.60M compared with $12.80M for Bolt Biotherapeutics (BOLT).

Are Actuate Therapeutics and Bolt Biotherapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons